Eli Lilly has confirmed plans for a $1.3 billion takeover bid for Verve Therapeutics, upgrading a collaboration between the ...

Eli Lilly's stock price has over-corrected following a downgrade in its outlook following the adjustment for acquisition ...

Meridian Dairy Days is just a few days away, and one of the most important events is the dairy goat and cattle shows that ...

Eli Lilly and Co. is shelling out $1 billion to buy a Boston biotech known for genetic medicines for cardiovascular disease.

Shares of Verve Therapeutics skyrocketed 75% in premarket trading Tuesday after Eli Lilly announced it would acquire the gene-editing startup for about $1.3 billion.

Verve Therapeutics’ stock rallies by a record 80% on Eli Lilly’s premium purchase price for the drug-development company.

Indianapolis: Eli Lilly and Company and Verve Therapeutics have announced a definitive agreement for Lilly to acquire Verve ...

Eli Lilly has struck a deal to buy Crispr gene-editing start-up Verve Therapeutics for up to $1.3bn, the latest acquisition ...

Eli Lilly will acquire gene-editing startup Verve Therapeutics for up to $1.3 billion, the companies said on Tuesday, to ...

Eli Lilly & Co. agreed to buy Verve Therapeutics Inc., a US biotech that’s seeking to use gene editing to prevent clogged arteries, for as much as $1.3 billion.

Lilly has struck multiple partnership deals with gene-editing companies in the last two years to expand its portfolio beyond ...

Discover the latest business news including rising gas prices, Zepbound shipments, At Home bankruptcy, and the Federal Reserve meeting.